 2005 |
|
 November 29 |
AnGes Group Forms Business Alliance with FALCO biosystems |
| November 22 |
Completion of Trial Subject Enrollment for U.S. Phase I Clinical Trial of HGF Plasmid for Ischemic Heart Disease (IHD) |
| October 11 |
Osaka University, AOKI and AnGes MG Joint Development Project Launched
- Development of Fully Bioabsorbable Next-generation Magnesium Stent - |
| October 4 |
Medical -Use Patent for HGF (VEGF) Gene Granted in the U.S.
− Covering Cerebrovascular Disorders − |
| October 3 |
Hosokawa Powder Technology Research Institute
Succeeds in Encapsulating Nucleic Acid Drug Developed by AnGes MG
within Drug Delivery System (DDS) Nanoparticles
− Evaluation of “Nucleic Acid DDS Preparation” Technology
for Inflammatory Dermatoses Begins − |
| September 26 |
Domestic Clinical Trial for NFκB Decoy Oligo Launched
− Phase I Clinical Trial in Atopic Dermatitis Commences − |
| August 15 |
Basic Patent for HVJ-E Is Granted in the U.S. Covering HVJ-E As a Foreign Gene Transferring Vector
(Patent for material, usage/transfection method and preparation process of HVJ-E) |
| August 10 |
Avontec (Germany) and AnGes MG to form an Alliance
-- Obtained a license of STAT-1 Decoy Oligo in Asi -- |
| August 10 |
Nikko Principal Investments Japan Ltd and AnGes MG Inc to form an alliance in Pharma/Lifesciences area
~ An Alliance Fund has been jointly established, and the first investment just completed to a drug development company ~ |
| July 25 |
Pharmaceuticals and Medical Devices Agency Completes Review of
Initial IND for NFκB Decoy Oligo
-
Phase I Clinical Trial in Atopic Dermatitis Underway
- |
| July 8 |
AnGes MG Forms Business Alliance with Alfresa Pharma Corporation
-
Joint Research on Atopic Dermatitis Therapeutic Medicine to Prepare
for AnGes MG Establishing its own Sales Network
- |
| June 21 |
Rush University Medical Center /USA and AnGes MG executes License Agreement
- AnGes obtains the exclusive right to develop and sell NFκB Decoy Oligonucleotide as a treatment for Disc Degeneration - |
| June 13 |
Basic patent of HGF gene therapy is granted in Europe
- Our foundation of HGF gene therapy international development is strengthened. - |
| June 8 |
AnGes MG Starts to Explore Feasibility of a New DDS Drug with MedGel
- Toward Expanding the Application Range of NFκB Decoy Oligo - |
| May 24 |
Execution of License Agreement with Vical (USA) related to Non-viral Gene Delivery Technology
--Obtained an exclusive right for HGF gene’s delivery-- |
| April 28 |
GenomIdea Launches Service with Mitsubishi Space Software
- Drug Design Service for Next-Generation Nucleic Acid Medicine “siRNA” - |
| April 27 |
Completion of Trial Subject Enrollment for the US Phase II Clinical Trial of HGF Plasmid for Peripheral Arterial Disease (PAD) |
| January 26 |
Launch of Joint Research Project between the University of Tokyo Hospital and AnGes MG
--To develop cutting-edge clinical medicine, including genetic medication and cell remediation medicines-- |
| January 24 |
The Research-and-Development Type Venture Business Consortium That Includes AnGes MG, To Receive Research Grant From New Energy and Industrial Technology Development Organization
--Development of NFκB decoy oligo therapeutic agent for IBD-- |
 |
|
